UNSPSC 51111876: Leuprorelin

This classification denotes a gonadotropin-releasing hormone analog, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier EFY6W0M8TG. European Medicines Agency schedules Leuprolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08449MIG. Leuprolide generally arises in the molecular formula C59H84N16O12. The term 'leuprolide' is a European Pharmacopoeia designation.

UNSPSC 51111876 Leuprorelin is a Commodity code covering pharmaceutical products supplied to state and local health systems and government facilities through cooperative purchasing vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, recently solicited manufacturers of generic multi-source pharmaceuticals and over-the-counter products to supply state and local jurisdictions including Oregon. The work involves supplying finished pharmaceutical products with specific National Drug Codes (NDCs) through authorized wholesale distributors—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—requiring vendors to certify compliance with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements. Vendors must maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place and carry comprehensive insurance including commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000.

The code shows activity centered on multistate cooperative purchasing structures serving multiple state and local government customers. MMCAP issued an RFP (S1070000015802) with a response deadline of March 26, 2026, seeking manufacturers to submit detailed product information, pricing in formats including flat price, net price structures (NF30, NF60, NF90), or WAC-minus pricing, and evidence of EDI capability. Evaluation weights favor price competitiveness (75 percent) with 10 percent on fixed pricing for the contract term, 5 percent each on administrative fee compliance, EDI capability, and agreement to a 3 percent administrative fee, and 5 percent on administrative format compliance. Awards are effective July 1, 2026, with contract terms of two years for new vendors and amendments aligning with existing agreements through June 30, 2028. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs, with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials.